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INTRODUCTION
Inflammatory bowel disease encompasses a number 
of chronic, relapsing inflammatory disorders involving 
the gastrointestinal tract.[1] The two primary types of 
inflammatory bowel disease are Crohn’s disease and 
ulcerative colitis. In inflammatory bowel diseases, the 
intestine (bowel) becomes inflamed, often causing recurring 
abdominal cramps and diarrhea. Although the exact cause 
of ulcerative colitis remains undetermined, the condition 
appears to be related to a combination of genetic and 
environmental factors. Among the pathological findings 
associated with inflammatory bowel disease are increases 
in certain inflammatory mediators, signs of oxidative stress, 
a deranged colonic milieu, abnormal glycosaminoglycan 
(GAG) content of the mucosa, decreased oxidation 
of short chain fatty acids (SCFAs), increased intestinal 
permeability, increased sulfide production, and decreased 
methylation. While not one factor has been identified 
as the initial trigger for inflammatory bowel disease.[2] 
Proteinase-activated receptors (PARs) have the common 
property of being activated by the proteolytic cleavage 
of their extracellular N-terminal domain. The new NH2
2 
terminus acts as a ‘tethered ligand’ binding and activating 
the receptor itself. Four members of this family have been 
cloned, three of which are activated by thrombin (PAR-1, 
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Role of the PAR-2 receptor in intestinal inflammation
PAR-3 and PAR-4) while the fourth (PAR-2) is activated 
by trypsin or mast cell tryptase.[3] In physiological or 
pathophysiological conditions, the gastrointestinal tract is 
exposed more than other tissues to proteinases (digestive 
enzymes, proteinases from pathogens or proteinases 
from inflammatory cells) that can activate PARs. Since 
PARs are highly expressed throughout the gastrointestinal 
tract,[4] the study of the role of PARs in these tissues 
appears to be particularly important. In inflammatory 
or allergic conditions, the proteinases that constitute the 
major agonists for PARs (thrombin, trypsin, and mast cell 
tryptase) are usually released.[5] Protease-activated receptor-
2-activating peptides induce leukocyte rolling, adhesion, 
and extravasations.[6] PAR receptor agonist also involve in 
release of mediators from mast cell[7] which have a role in 
development of inflammation. The activation of PARs by 
these proteinases might contribute to the gastrointestinal 
inflammation.[8] Particularly PAR-2 receptor is involved 
in development of inflammation.[9] The role of PAR-2 
during intestinal inflammation is still unclear due to the 
fact that PAR-2 activating peptide had both pro- and anti-
inflammatory properties. PAR-2 is strongly expressed in 
the small intestine, colon, liver, pancreas and more weakly 
detected in the stomach. PAR-2 is also highly expressed 
by human colon adenocarcinoma cells.[10] This study was 
carried out to investigate the role of PAR-2 activation in 
the process of inflammation in the gut.
MATERIALS AND METHODS
Animals
Adult albino (Wistar strain) rats of either sex weighing 
between 200 and 250 g housed in standard conditions of 
temperature (22 6 2°C), relative humidity (55 6 5%), and 
light (12 h light/dark cycles) were used. They have been fed 
with standard pellet diet and water ad libitum. Animal were 
approved by the Institutional Animal Ethics Committee 
(IAEC) according to the regulation of Committee for 
the Purpose of Control and Supervision of Experiments 
on Animals (CPCSEA). Throughout the experiments, 
animals were handled according to the suggested ethical 
guideline for the care of laboratory animals.
Experimental protocol[11]
•  Control: Saline treated;
•  Model: TNBS (2, 4, 6-trinitrobenzenesulfonic acid, 
0.25 ml, 120 mg/ml in 50% ethanol, intrarectally) on 
1st day only;
•  Group 1: TNBS (0.25 ml, 120 mg/ml in 50% ethanol, 
intrarectally), on 1st day only 1 Trypsin (500 mg/kg, 
intrarectal) treatment continued till 20th day
•  Group 2: TNBS (0.25 ml, 120 mg/ml in 50% ethanol, 
intrarectally) on 1st day only 1 Trypsin (1 mg/kg, 
intrarectal) treatment continued till 20th day
•  Group 3: TNBS (0.25 ml, 120 mg/ml in 50% ethanol, 
intrarectally) on 1st day only 1 Trypsin (5 mg/kg, 
intrarectal) treatment continued till 20th day;
TNBS was delivered by a Teflon cannula (outside diameter 
1.2 mm, inserted 8 cm) through the anus of each rat. 
Ethanol evokes an acute inflammatory response which 
resolves spontaneously after 1 week. Therefore, we 
preferred to include a saline-treated group as a negative 
control instead of an ethanol-treated group. Various 
physical parameters such as body weight, food intake, and 
water intake were measured on 1st and 20th days. On 20th day, 
animals were sacrificed by cervical dislocation and dissected 
open to remove GIT (from stomach to anus). GIT was 
flushed gently with saline and cut open. Weight of the colon 
taken was measured and then the colon mucosa damage 
index (CMDI) [Figure 1] and the histopathological score i.e. 
disease activity index (DAI) were evaluated. Colon samples 
were taken for determinations of myeloperoxidase (MPO). 
Percentage protection of the mast cell degranulation in 
the mesentery of intestine of the rat was also measured.
Assessment of the colon mucosa damage index
The colon segment taken 10 cm proximal to anus of the 
sacrificed rats was excised longitudinally, was rinsed with 
saline buffer and fixed on a wax block. Each colon was 
observed and evaluated by two independent observers. 
Macroscopic scoring was done evaluated according to the 
formula of CMDI reported by Wei et al., 2003.[12] Briefly 
describe as follows:[1] 0-normal mucosa, 1-mild hyperemia, 
no erosion or ulcer on the mucosal surface,[2] 2-moderate 
hyperemia, erosion appearing on the mucosal surface,[3] 
3-severe hyperemia, necrosis and ulcer on the mucosal 
surface with the major ulcerative area extending ,40%,[4] 
4-severe hyperemia, necrosis and ulcer on the mucosal 
surface with the major ulcerative area extending .40%.
Assessment of disease activity index
The colon tissue samples taken for histology were fixed 
overnight in 4% neutral buffered formalin, processed, 
sectioned (4 mm thick), and stained with hematoxylin 
and eosin [Figure 2]. Each colon sample was observed 
and evaluated by two independent observers. To assess 
the histopathological score was assessed according to the 
modified model of the system reference given by Wei 
et al., 2003, which are as follows: (1) The infiltration of 
acute inflammatory cells: 0-no, 1-mild increasing, 2-severe 56   J Young Pharm Vol 2 / No 1
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increasing; (2) The infiltration of chronic inflammatory 
cells: 0-no, 1-mild increasing, 2-severe increasing; (3) The 
deposition of fibrotin protein: 0-negative, 1-positive; (4) 
the submucosa edema: 0-no, 1-patchy-like, 2-fusion-like; (5) 
the epithelium necrosis: 0-no, 1-limiting, 2-widening; (6) the 
epithelium ulcer: 0-negative, 1-positive.
Determination of the myeloperoxidase in the colon
The  colon  sample  was  homogenized  (50 g/l)  in 
50 mmol/l ice-cold potassium phosphate buffer (pH 6.0) 
containing 0.5% of hexadecyltrimethylammonium 
bromide. The homogenate was first frozen and thawed 
thrice for three times, and then centrifuged at 4000 rpm 
for 20 min at 4°C for the measurement of myelopeoxidase 
(MPO) activity. MPO, a marker of neutrophil migration 
Figure 1: Effect of trypsin on the weight of the colon in TNBS-induced 
inflammatory bowel disease in rats. (Control is only saline treated, 
model group is only  TNBS treated.); *When compared to control 
P , 0.001; #When compared to model P , 0.001; $When compared 
to model P , 0.01. One-way ANOVA (n 5 6)
Figure 2: Tissue histopathology. Control group: Shows normal mucosa (a), Model group: Shows severe hyperplasia, ulcer appearing on the mucosal 
surface with the major ulcerative area extending .40% (b), Group 1: Shows severe hyperplasia, ulcer appearing on the mucosal surface with the major 
ulcerative area extending .50% (c), Group 2: Shows severe hyperplasia and ulcer appearing on the mucosal surface with the major ulcerative area 
extending .55% (d), Group 3: Shows severe hyperplasia, ulcer appearing on the mucosal surface with the major ulcerative area extending .60% (e)J Young Pharm Vol 2 / No 1  57
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into an antigen. It has shown that it can elicit immunologic 
responses, induce generation of inflammatory bowel 
disease (IBD).[15,16] This model shares many of the 
histopathological and clinical features of human IBD and 
is useful for the study of the etiopathogenesis of chronic 
colon inflammation as well as providing an inexpensive 
model suitable for assessing therapeutic agents. 
In IBD, body weight, food intake, and water intake are the 
important indicators of the severity of this disease. As there 
is a severe inflammation in the colon, the tolerability to 
the food and water decreases, and therefore body weight 
also decreases.[17] In our study we found that the treatment 
with trypsin decreased food and water intake. Weight loss 
is also increased.
In IBD, weight of colon is increased due to severe 
was estimated by measuring H2O2
2 dependent oxidation 
of O dianisidine.[13]
% Mesenteric mast cell protection
% Mast cell protection is suggested by a decrease in the 
degranulation of the mast cell. Mesentery of intestine 
from obtained the animals was removed and placed in 
the Ringer Locke solution (NaCl 0.9%, KCI 0.042%, CaCl2 
0.024%, NaHCO3 0.015%, and dextrose 0.1%). Then it was 
stained and fixed with the 4% formaldehyde containing 
0.1% toluidine blue. % Mast cell protection was evaluated 
microscopically at 340 magnification.[14]
Statistical analysis
Data obtained from the animal experiments were expressed 
as the mean 6 SEM of six observations. The statistical 
difference was evaluated by one-way ANOVA. Differences 
were accepted as statistically significant when P , 0.05.
RESULTS
On 1st and 21st days, changes in the physical parameters 
including body weight, food intake, and water intake were 
measured [Table 1]. When compared with the control group, 
significant reductions in all these parameters were observed 
with the model group. However, in the animals treated with 
trypsin, still high reduction in the body weight, food intake 
and water intake was found compared to the model group.
Animals treated with TNBS showed high colon weight 
compared to saline-treated animals. Animals treated with 
trypsin showed high colon weight compared to only TNBS 
treated. That means trypsin treatment increase severity 
of inflammation.
The main parameters used for evaluating the degree of 
colonic inflammation in IBD were CMDI, DAI. In this 
study, significant increases in CMDI and DAI were found, 
when compared with that of only TNBS-treated animals 
[Table 2]. 
Animals treated with typsin showed high MPO activity 
compared only TNBS treated animals [Table 3]. Also 
there is high mast cell degranulation with trypsin treatment 
compare to TNBS alone [Table 3].
DISCUSSION
TNBS is a hapten compound, and when it is bound with 
a substance of high molecular tissue proteins, it will turn 
Table 3: Effect of trypsin on myelopeoxidase and mast 
cell degranulation in TNBS-induce inflammatory bowel 
disease in rats
Groups MPO (unit/mg 
of protein)
Mast cell degranulation 
(% protection)
Saline treated  22 6 0.9 80 6 1.5
Only TNBS treated 68 6 2.5* 15 6 0.5*
Trypsin (500 mg/kg) 79 6 1.2# 11 6 1.0#
Trypsin (1 mg/kg) 90 6 15# 9 6 0.8#
Trypsin (5 mg/kg) 99 6 1.8# 7 6 0.9#
Each value presented as mean 6 SEM (n 5 6) (one way ANOVA); *Compared with 
control group P , 0.001; #Compared with model group P , 0.001.
Table 1: Effect of trypsin on water intake, food intake, 
and body weight in TNBS-induced inflammatory bowel 
disease in rats
Groups Reduction in 
body weight (g)
Reduction in food 
intake (g/group)
Reduction in 
water intake 
(ml/group)
Saline treated  7 6 1 5 6 0.8 5 6 1.8
Only TNBS treated 50 6 2.5* 50 6 4* 45 6 1.2*
Trypsin (500 mg/kg) 59 6 2# 57 6 3.9# 54 6 2#
Trypsin (1 mg/kg) 61 6 2.9# 60 6 5.2# 58 6 1.1#
Trypsin (5 mg/kg) 72 6 3.5# 66 6 4.4# 63 6 2.1#
Each value presented as mean 6 SEM (n 5 6) (one-way ANOVA); *Compared with 
control group, P , 0.001; #Compared with model group, P , 0.001
Table 2: Effects of trypsin on CMDI, DAI, and 
MPO activity in the colon tissue of TNBS-induced 
inflammatory bowel disease in rats
Groups CMDI DAI
Saline treated 0.0 6 0.0 0.7 6 0.11
Only TNBS treated 6.1 6 0.31* 8.3 6 0.2*
Trypsin (500 mg/kg)  7 6 0.21# 9.2 6 0.10#
Trypsin (1 mg/kg)  7.8 6 0.13# 9.9 6 0.13#
Trypsin (5 mg/kg) 8.5 6 0.18# 11.5 6 0.11#
(CMDI: Colonic mucosal damage index, DAI: Disease activity index); Each value 
presented as mean 6 SEM (n 5 6) (one-way ANOVA); *when compared to control 
group P , 0.001; #when compared to model group P , 0.001.58   J Young Pharm Vol 2 / No 1
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inflammation and edema.[18] Animal treated with TNBS 
showed high colon weight compare to normal animals. 
Treatment with trypsin increased colon weight of animals 
compared to animals treated only with TNBS. That shows 
that typsin increase inflammation and edema.
In our study, we induced IBD by intrarectal administration 
of TNBS in animals. The severity of colonic inflammation 
in developed disease was evaluated by measuring main 
parameters CMDI and DAI scores and MPO activity. 
In present study, we found that increased in progression 
of the disease pathogenesis following treatment with 
trypsin characterized by significantly increased in the 
score of CMDI and DAI compared to the model 
group which is also supported by the changes in the 
histopathology of the colon. MPO is an enzyme found 
in the neutrophils and can be used as a quantitative index 
of inflammation in colonic tissue. MPO activity may be 
regarded as an index of inflammation damage. The main 
pathological feature of IBD is transmural infiltration of 
polymorphonuclear neutrophils and MPO is released from 
these neutrophils.  [19,20] Treatment with trypsin significantly 
increased the level of MPO compared to the model group 
which indicates that trypsin increases the infiltration of the 
inflammatory cells which are responsible for increasing the 
progression of the disease condition.
Mast cell degranulation causes mucus secretion, mucosal 
edema, increased gut permeability, and release of various 
inflammatory mediators that may be responsible for 
some of the signs and symptoms of inflammatory bowel 
disease.[21] In our study, a significant rise in the mast cell 
degranulation was observed in the TNBS-treated animals, 
while in trypsin-treated animals, mast cell degranulation 
was significantly higher. That is because trypsin increased 
mediator release from mast cell through PAR-2 receptor.  [7] 
This observation clearly indicates that trypsin increase 
severity of the injury produced by inflammatory mediators 
released from the mast cell degranulation.
CONCLUSION
From the results of the present study, it can be concluded 
that trypsin increases the severity of the IBD and this may 
be because of the action of trypsin on PAR-2 receptors 
present in colon. PAR-2 receptor may have important 
role in inflammation of gut. Further study using PAR-2 
antagonists is required to carry out to establish role of 
PAR-2 in intestinal inflammation.
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